Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer

• 資料種別: 記事
• タイトル: Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
• 著者標目: S Whyte; A Pandor; M Stevenson; A Rees
• 出版年月日等: 2010-10
• 出版年（W3CDTF）: 2010-10
• タイトル（掲載誌）: Health Technology Assessment
• 巻号年月日等（掲載誌）: 14 Suppl 2
• 掲載巻: 14
• 掲載号: Suppl 2
• 掲載ページ: 47-53
• 掲載年月日（W3CDTF）: 2010-10
• ISSN（掲載誌）: 13665278
• 出版事項（掲載誌）: National Institute for Health and Care Research
• 件名標目: Health Policy
• 対象利用者: 一般
• DOI: 10.3310/hta14suppl2/07; https://doi.org/10.3310/hta14suppl2/07
• 作成日（W3CDTF）: 2014-10-13
• 著作権情報: http://www.nationalarchives.gov.uk/doc/non-commercial-government-licence/non-commercial-government-licence.htm
• 関連情報（URI）: https://njl-admin.nihr.ac.uk/document/download/2035676; https://www.journalslibrary.nihr.ac.uk/publications/hta14Suppl2-07/hta14Suppl2-07.xml
• 参照: CapeOX＋bevacizumab療法で切除可能となった局所進行大腸癌の１例; https://cir.nii.ac.jp/crid/1390282679321903616
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Crossref; https://www.crossref.org

• 要約等: <jats:p>This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of bevacizumab ...